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a b s t r a c t
INTRODUCTION: Intestinal angiosarcomas are an extremely rare and aggressive vascular tumors, with a
few cases reported in the literature.
PRESENTATION OF CASE: A 45 years-old male arrived to our hospital with intermittent gastrointestinal
bleeding presenting melena and weight loss, he has antecedent of pelvic radiotherapy ten years before
admission for an unknownpelvic tumor. Emergency surgerywas required because of uncontrolled bleed-
ing and hemodynamic instability. Histopathological ﬁndings revealed amultifocal high-grade epithelioid
angiosarcoma, with cells reactive for CD31, keratins CKAE 1/AE3 and factor VIII.
DISCUSSION:Angiosarcomas are aggressive tumorswith a high rate of lymphnodemetastasis and periph-
eral organs. The diagnosis is difﬁcult because it present nonspeciﬁc clinical presentation, radiological
and histopathological ﬁndings. There are few reports of angiosarcoma involving the small intestine and
the most common presentation are abdominal pain and gastrointestinal bleeding. There is not enough
information for intestinal angiosarcoma secondary to radiation therapy, but there have been proposed
criteria for diagnosis: no microscopic or clinical evidence of antecedent malignant lesion, angiosarcoma
presented in the ﬁeld of irradiation, long latency period between radiation and angiosarcoma and histo-
logical conﬁrmation. We suspect our patient course with a secondary form of angiosarcoma. Therapy for
bleeding angiosarcoma consists in control of bleeding and medical management to stabilize the patient.
Once accomplished surgical resection is required.
CONCLUSION: We should keep in mind this tumors as a cause of obscure intestinal bleeding in patients
with medical history of radiation therapy.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Angiosarcomas are a very rare and aggressive tumors of vascular
cell origin, they comprise 1–2% of all sarcomas. They can occur any-
where on the body but they occurmainly in the skin, soft tissue and
breast and rarely the gastrointestinal tract [1,2]. They can be spo-
radic or secondary to some predisposing factors like radiotherapy,
chronic lymphedema, familial syndromes and exposure to various
chemicals. The distribution is similar between males and females
and they are more common in old people [3]. These neoplasms
have a very poor prognosis due to its diagnostic is usually delayed
because of its diverse clinical presentation and none speciﬁc symp-
toms [4]. The occurrence in small intestine is extremely rare, with a
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few reports in the international journals [5]. We describe a case of
patient who presented gastrointestinal bleeding due to multifocal
intestinal angiosarcoma.
2. Clinical case
A45years-oldmalewas admitted in ourhospitalwith a3month
history of intermittent gastrointestinal bleedingpresentingmelena
and weight loss of 20kg. At his arrive, he reported epigastric pain
and occasional fever since amonth ago. The patient referred amed-
ical history of 20 pelvic radiotherapy sessions in a private hospital
for unknown pelvic tumor 10 years before its admission. Diagnos-
tic workup began with an upper endoscopy and colonoscopy with
a negative report of visible bleeding and non-anatomical abnor-
malities. A computer tomographic scan of the abdomen showed
irregular and circumferential thickening of jejunum,with 24mmof
thickness, without lymph nodes and other intra-abdominal lesions
(Figs. 1 and 2). Serum levels of tumors markers ACE and Ca 19.9
http://dx.doi.org/10.1016/j.ijscr.2015.03.049
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. CT scan, axial plane show an intestinal tumor.
were normal, except Ca 125 thatwas increased 4 fold normal value.
Conservative management was started with hemodynamic stabi-
lization andmultiple transfusions (packed red blood cells and fresh
frozen plasma).
We decided an emergency surgery in his third day of admis-
sion because high transfusional requirements and hemodinamical
instability. An exploratory laparotomy was performed ﬁnding
macroscopic evidence of four tumors at 15, 30, 50 and 150 cm
distal to Treitz’s ligament (Fig. 3); therefore, three intestinal resec-
tions with enteroenterostomy and omentectomy were performed.
No transoperative complications were reported. The postoperative
course was complicated by surgical site infection and the patient
Fig. 2. CT scan, coronal plane showing thickening of intestinal wall.
Fig. 3. Intraoperative presentation of the multifocal tumors.
was treated with IV antibiotics, he was discharged 10 days after
surgery. The patient was referred to Oncology center to receive
adjuvant therapy.
The pathological ﬁndings revealed a multifocal high-grade
epithelioid angiosarcoma, with cells reactive for CD31, keratins
CKAE 1/AE3 and factor VIII, and nonreactive for CD34 involving
ileum and jejunum with diameter 4.5, 6.5 and 8.5 cm, highly vas-
cularized, ulcerated and inﬁltrating tumors, with focal vascular
permeation, without lymphatic and neural permeation, no necro-
sis. Six omentum metastatic implants were reported.
3. Discussion
Primary angiosarcoma of the small intestine is an extremely
rare disease affecting mainly: liver, spleen, adrenals, ovaries, heart,
lung, breast and, rarely, the middle gastrointestinal tract as in our
case [2]. Angiosarcomas are aggressive tumors with a high rate
of lymph node metastasis and peripheral organs. The diagnosis is
difﬁcult because of nonspeciﬁc clinical presentation, radiological
and histopathological ﬁndings, so the angiosarcoma of the small
intestine represents unique challenge to diagnose [6].
These tumors could have clinical presentation with bleeding
of gastrointestinal tract, anemia, intestinal obstruction, abdomi-
nal pain, nausea, abdominal distention, weight loss, shortness of
breath, weakness and diarrhea. In our case, present a patient with
gastrointestinal bleeding like initial symptom [2,7,8]. There is a
recent report presented giant abdominal angiosarcoma (diame-
ter >20 cm) [7].
Ni et al., reported 27 cases of angiosarcoma involving the small
intestine [2]. The most common presentation was abdominal pain
and gastrointestinal bleeding (37%). Twenty-three patients pre-
sented primary angiosarcoma (85.15%), 4 patients indeterminate
(14.8%) and none with secondary form of angiosarcoma. Nine
patients had medical history of radiation (33.3%) all of these
with the primary form. One patient had multifocal intestinal of
angiosarcoma and no history of radiation, being a primary form
of angiosarcoma. Our case, as we have described, the patient pre-
sented gastrointestinal bleeding caused by a multifocal intestinal
angiosarcoma, and because the history of pelvic radiation, we sup-
posed that, this presentation was a secondary form of intestinal
sarcoma [2].
Angiosarcomas are classiﬁed as well-differentiated, poorly dif-
ferentiated, and epithelioid tumors [5]. The histopathological
diagnosis is difﬁcult because it shows high architectural and
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cytological variability [9]. The vasoformative structures can range
from well-formed vessels, recognized as vascular spaces to slit-like
poorly developed anastomosing vascular channels [9,10].
In well differentiated areas, these tumors form functioning vas-
cular sinusoids continuous with normal vascular channels, this
dissect between collagen bundles and are often associated with
monocyte inﬁltration [3].
In aggressive disease, cells become multilayered and form
papillary-like projections into the vascular lumen, mitotic bodies
are common, as are small clusters of erythrocytes within the cyto-
plasm of the abnormal endothelial cells. In poorly differentiated
areas, the malignant endothelial cells form continuous sheets, usu-
ally with an epithelioid morphology, and with areas of hemorrhage
and necrosis can be confused with other entities such as a poorly
differentiated carcinoma, melanoma, or epithelioid leiomyosar-
coma [3,9].
Expression of endothelial markers including von Willebrand
factor, CD34, CD31, Ulex europaeus agglutinin 1, and vascu-
lar endothelial growth factor (VEGF) are present, and are very
important to conﬁrm the diagnosis [3,5]. They are the most use-
ful markers in poorly differentiated cases. However, progressive
tumors dedifferentiation can lead to a loss of these markers. The
absence of melanocytic markers (S100), human melanoma black-
45, and melanoma antigen can help distinguish angiosarcoma
from melanoma [3,11]. Additionally, epithelioid angiosarcomas
can express cytokeratins, leading to confusion with poorly differ-
entiated carcinomas. Beneﬁts diagnosis by immunohistochemical
expression of CD31 and CD34 markers as well as the factor VIII
antigen-active ated [5,11]. The role of angiogenesis and the angio-
genic factors, VEGF-A are an important area of opportunity for
the diagnosis because is consistently expressed at higher concen-
trations in angiosarcomas. The VEGFR-2 is the main receptor and
its loss, was correlated with worse prognosis [3,12]. Other abnor-
malities have been found in metastasic angiosarcoma, TP53, KRAS
mutations, overexpression of Wilms’ tumor-1 and galectin-3. The
overexpression of the transcription factor ETS1 result in increased
production of metalloproteinases [3].
Results pooled from three separate series showed KIT pos-
itivity in 38 (50%) of 76 samples, and diffuse KIT expression
in 18 (47%) of 38 samples. KIT-mutation analysis has been
done for a handful of angiosarcomas [13]. Multiple chromoso-
mal abnormalities have been described but none is speciﬁc for
angiosarcom (trisomy 5, deletions on the short arm of chromo-
some 7, abnormalities on chromosomes 8, 20, and 22, and loss of
chromosome Y [3].
There is not enough information for angiosarcoma secondary
to radiation therapy, but there have been proposed criteria for
diagnosis: no microscopic or clinical evidence of antecedent malig-
nant lesion, angiosarcoma presented in the ﬁeld of irradiation, long
latency period between radiation and angiosarcoma and histolog-
ical conﬁrmation. As we mentioned before, we suspect our patient
coursewith a secondary form of angiosarcoma because accomplish
with this criteria [14].
CT and MRI scan has limited diagnostic utility due to lack of
speciﬁcity. Endoscopy can directly detect neoplasia, and it is useful
in gastric location, duodenum or colon. For tumors of the jejunum
and ileum, capsule endoscopy and barium studies may be used
but have limited diagnostic use. Exploratory laparotomy is often
required to reach a diagnosis. In our case, we required surgical
exploration due to hemodynamic instability and failure with con-
servative management [6].
Therapy for bleeding angiosarcoma consists in control of bleed-
ing and medical management to stabilize the patient. Once
accomplished, is followed by surgical resection [5]. Surgery
is the treatment of choice, although usually is not possible
due to advanced stage when the diagnosis is made. Currently,
surgical excision associated with adjuvant radiotherapy and /or
chemotherapy may be useful; however, the efﬁcacy of these treat-
ments for angiosarcoma remains unclear [5].
Guidelines for neoadjuvant and adjuvant therapy are not
well described. Literature reports showed poor experience in
management with adjuvant chemotherapy and a combination
chemotherapy and radiation. There are experiences with adjuvant
paclitaxel and combinationof doxorubicin, vincristine, dacarbazine
and cyclophosphamide; another combination is with doxorubicin
and dacarbazine, and monotherapy with doxorrubicin but these
protocols are generally empiric and based on studies of cuta-
neous angiosarcoma. Clinical studies on intestinal angiosarcomas
are lacking due to their rarity, and results are diverse, but generally
withpoorprognosis [5]. No current recommendations canbemade,
but a combination of paclitaxel and thalidomide are commonly
considered as adjuvant therapy [15].
Prognosis in these type of tumors is very poor despite the use of
chemotherapy, surgeryandeven radiotherapy. There isnoevidence
which can demonstrate a better survival among trials and they
are usually empiric due to the lack of experience. Patients usually
die within 1 year from diagnosis or even on the late posoperatory
period due to severe sepsis [5].
Although some trials report certain association of the site of pre-
sentationwith prognosis, other do not do it, speciﬁcally speaking of
intestinal angiosarcomas; there are no guidelines referring to the
follow up, which needs overall focused to detect metastasis and
recurrence. Main prognostic factors such as older age, status per-
formance, high tumor grade and metastases are associated with a
poorer prognosis, but it is unclear which is the main factor [3].
Recurrence cannot be discussed until metastases has been dis-
carded and follow up in patients free of disease is documented. In
Ni et al. report, of the 27 patients, 26% (7 patients) died during the
ﬁrst six months, 15% (4 cases) died of several complications after
1 year of surgery, 18.5% (5 cases) died during posoperatory period
and a the rest of them (33%) did not have any follow up [2].
4. Conclusions
Our patient presented a very rare condition, that start with non
speciﬁc symptoms, so we started the work-up ﬁnding an intestinal
tumor and because the patient presented an hemodynamic deteri-
oration, we decide to submit to surgery. Our patient had a history
of unknown pelvic tumor and radiotherapy. So, we suggest to con-
sider thediagnosisof intestinal angiosarcoma inotherpatientswith
these features. After the pathology results, the patient was sent to
oncologic management.
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